We used surface staining against the B10/Breg markers CD5, CD1d and Granzyme B in combination with CD19 and were able to identify cells with a Breg phenotype in wild-type controls but not in tumor-bearing recipients of T and B cells (data not shown). This evidence concerns the gene GZMB and neoplasm.